quinoxalines has been researched along with exenatide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flatt, PR; Green, BD; Irwin, N; Patterson, S | 1 |
| Cheong, YH; Kaang, BK; Kim, MK; Son, MH | 1 |
| Guan, S; Li, X; Liu, Y; Ma, X; Meng, J; Qu, D; Wang, L; Wang, N; Wang, X; Zhang, H; Zhou, S; Zhou, Y | 1 |
3 other study(ies) available for quinoxalines and exenatide
| Article | Year |
|---|---|
Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
Topics: Animals; Biomimetic Materials; Blood Glucose; Cell Line; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Mice; Molecular Weight; Peptides; Quinoxalines; Receptors, Glucagon; Sulfones; Venoms | 2010 |
Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
Topics: Animals; Calcium; CHO Cells; Cricetinae; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Peptides; Pyrimidines; Quinoxalines; Receptors, Glucagon; Sulfones; Venoms | 2012 |
An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke.
Topics: Administration, Oral; Allosteric Regulation; Animals; Apoptosis; Blood Glucose; Brain; Cell Survival; Cells, Cultured; Drug Evaluation, Preclinical; Exenatide; Glucagon-Like Peptide-1 Receptor; Infarction, Middle Cerebral Artery; Inhibitory Concentration 50; Insulin; Male; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Peptides; Primary Cell Culture; Quinoxalines; Reperfusion Injury; Sulfones; Venoms | 2016 |